![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, November 26, 2018 3:59:13 PM
Here is a snip:
“Given the notable interest from global and specialty pharmaceutical companies that we have received following recent Brilacidin-OM data releases, we continue to carefully assess all of our potential alliance opportunities—toward cementing the best pathway forward,” said Leo Ehrlich, Chief Executive Officer of Innovation Pharmaceuticals. “The expedient advancement of Brilacidin-OM into later clinical development is a priority, as is the broader expansion of the complete Brilacidin Franchise.”
http://www.ipharminc.com/press-release/2018/5/9/innovation-pharmaceuticals-concludes-data-analysis-of-its-phase-2-clinical-trial-for-severe-oral-mucositis-in-head-and-neck-cancer-positioning-to-fill-a-substantial-void-in-supportive-cancer-care
"COMPANIES" Alot to digest and allow COMPANIES to do more DD starting in May. How many came and gone from May through August, who knows? All we know was in August a Term Sheet was signed for B-OM and B-IBD. However, more DD was in the cards. You nor I know if that same Term Sheet is in tact or if there are others.
However, common sense as one poster suggested back in September, there will not be a deal until the EOP 2 Meeting is over. This meeting is CRITICAL and will explain the path moving forward. A partner will need to know this information, why put up milestones and unrealistic monies when everyone can wait until December to know what we are looking at.
I am eagerly awaiting the info on how this product pushes forward. Do we stay with the liquid, do we move to sachets, do we skip to phase 4? Mouthwash has a much quicker path to approval compared to IV and pills. Swish and spit and B-OM can reduce SOM by 75% in the most severe cases using the highest dose of cisplatin. This showed a 60% plus difference over placebo. Start there and expand to other cancers and other types. This is a billion dollar possibility.
You are always so harsh and negative about this company and I think you should reconsider and look at the facts from their website and PR's instead of just looking at the share price. We know the current financing is ugly and causing this great depression of share price, but the drugs and company are actually lightyears above this share price. imo
http://www.ipharminc.com/press-release/2018/9/24/innovation-pharmaceuticals-provides-a-comparative-perspective-on-brilacidins-potential-to-unlock-the-oral-mucositis-market-pharma-industry-attacks-severe-pain-and-suffering-due-to-cancer-treatments
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM